Nasdaq IPOs

Inozyme Pharma, a preclinical biotech developing protein therapies for rare calcification diseases, raised $112 million by offering 7 million shares at $16, in line with the upwardly revised terms. The company offered 0.5 million more shares than anticipated. It originally f

Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised $251 million by offering 14.8 million shares at $17, above the narrowed range of $15 to $16. The company offered 2.3 million more shares than anticipated. It originally planned to offer 10 m

iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing, iTeos commands a fu

Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, raised $209 million by offering 11 million shares at $19, above the narrowed range of $17 to $18. The company originally planned to offer 8.8 million shares at a range of $16 to $1

Greencity Acquisition, a blank check company focused on businesses in Asia, raised $40 million by offering 4 million units at $10. Each unit consists of one share of common stock and one warrant, exercisable at $11.50. At pricing, Greencity Acquisition commands a market value of

PaxMedica, a Phase 2 biotech developing therapies for neurodevelopmental disorders, announced terms for its IPO on Thursday. The Woodcliff Lake, NJ-based company plans to raise $15 million by offering 2.5 million shares at a price range of $5.50 to $6.50. At the midpoint of the p

Duck Creek Technologies, which provides a SaaS platform that streamlines business processes for P&C insurers, filed on Thursday with the SEC to raise up to $200 million in an initial public offering. The company's Duck Creek Suite enables carriers to develop and manage policy

Ascendant Digital Acquisition, a blank check company targeting an interactive digital entertainment business, raised $360 million by offering 36 million units at $10. The company originally planned to offer 30 million units. Each unit consists of one share of common stock and one

Inhibikase Therapeutics, a clinical stage biotech developing therapies for Parkinson's and related disorders, filed on Thursday with the SEC to raise up to $18 million in an initial public offering. The company's pipeline contains lead candidate IkT-148009, a c-Abl protein k

Billionaire Elon Musk's SpaceX is looking to raise new capital at a valuation of about $44 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Pershing Square Tontine Holdings (PSTHU) raised $4 billion and traded up 6.5% yesterday, becoming the largest Special Purpose Acquisition Company (SPAC) ever to go public. It is the latest milestone in a record-breaking year for SPACs. To screen for upcoming or past SPAC IPOs, si

Pershing Square Tontine Holdings (PSTHU) raised $4 billion and traded up 6.5% yesterday, becoming the largest Special Purpose Acquisition Company (SPAC) ever to go public. It is the latest milestone in a record-breaking year for SPACs. To screen for upcoming or past SPAC IPOs, si

Inozyme Pharma, a preclinical biotech developing therapies for diseases of abnormal mineralization, raised the proposed deal size for its upcoming IPO on Thursday. The Boston, MA-based company now plans to raise $104 million by offering 6.5 million shares at $16. The company had

Vasta Platform, a Brazilian provider of K-12 school curriculum solutions being spun out of Cogna, announced terms for its IPO on Thursday. The São Paulo, Brazil-based company plans to raise $306 million by offering 18.6 million shares at a price range of $15.50 to $17.50.

AlloVir, a Phase 2 biotech developing allogeneic T cell therapies for viral diseases, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $251 million by offering 14.8 million shares at a price range of $16 to $18. At the midpoint of the propos

Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The San Francisco, CA-based company now plans to raise $193 million by offering 11 million shares at a price range of $17 to $

Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $194 million by offering 12.5 million shares at a price range of $15 to $16.

Skillful Craftsman Education Technology, which provides online education and technology services in China, raised $15 million by offering 3 million shares at $5, the midpoint of the range of $4.50 to $5.50. At pricing, the company commands a market value of $62 million. Skillful

East Resources Acquisition, a blank check company formed by Terrence Pegula targeting the North American energy industry, raised $300 million by offering 30 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50.&nbs

Montrose Environmental Group, which provides a suite of environmental impact services, raised $150 million by offering 10 million shares at $15, the low end of the range of $15 to $17. At pricing, the company commands a fully diluted market value of $523 million, which includes $